Iterum Therapeutics(US:ITRM)2025-11-14 14:30Financial Data and Key Metrics Changes - Iterum generated net product sales of $0.4 million in Q3 2025, which included initial stocking at specialty pharmacies [21] - Total operating expenses were $8.1 million in Q3 2025, compared to $4.9 million in Q3 2024, reflecting increased commercialization activities [21][22] - The net loss on a US GAAP basis was $9 million for Q3 2025, compared to a net loss of $6.1 million for Q3 2024 [24] Business Line Data and Key Metrics Changes - The launch of Orlyvah began on August 20, 2025, with over 280 prescriptions generated by more than 100 unique prescribers by November 12, 2025 [9][12] - Approximately 40% of Orlyvah prescriptions have been filled through payer approval processes, aligning with expectations [10] Market Data and Key Metrics Changes - Orlyvah's access now reaches 16% of insured lives, with increasing adoption by employer groups and payer formularies [16] - A signed rebate agreement with a top Medicare Part D pharmacy benefit manager allows Orlyvah to be added to formularies for coverage beginning in 2026 or 2027 [15] Company Strategy and Development Direction - The company plans to raise additional capital to support ongoing commercialization efforts and potentially expand into high-value territories [19] - Iterum aims to generate revenue in excess of expenses and become self-funding over the next couple of years [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the feedback from physicians, payers, and patients regarding Orlyvah, indicating a positive trajectory for revenue growth [20] - The company expects modest sales in Q4 2025 and anticipates net product revenue for 2026 to be between $5 million and $15 million [18] Other Important Information - Iterum's cash and cash equivalents at the end of September 2025 were $11 million, providing an operating runway into Q2 2026 [24][25] - The company has reduced its in-person field team to 10 representatives and is augmenting efforts with virtual sales representatives [14] Q&A Session Summary Question: Will the company report specific launch metrics in the coming quarters? - The company plans to report metrics such as prescriptions, growth, and number of physicians to track the launch [27][28] Question: Can the company provide more details on payer coverage and uptake? - Feedback from physicians has been positive, particularly regarding Orlyvah's ability to keep patients out of the hospital [31][32] Question: What marketing strategies are being considered to drive uptake? - The company is focusing on field organization investments and is considering social media and other marketing channels for future engagement [40][52]